CTD² Centers

 

The CTD2 Network focuses on identifying and understanding (1) pathways that influence cancer phenotypes (including understanding the function of the genes/target that are essential during cancer initiation, progression and maintenance); (2) perturbagens, singly or in combination, that can modulate such pathways; and (3) biomarkers which predict responses to treatments, help determine prognosis, and/or contribute to understanding of other aspects of cancer etiology to enable the development of effective therapeutic modalities in the future. The Network also addresses whether these findings are dependent on the defined genetic background (either germline or somatic) of the patient.

CTD² Network is comprised of 12 OCG-supported research teams, called Centers, led by a principal investigator. The Centers work independently as well as collaboratively as a “Network”. Network Centers utilize a combination of state-of-the-art high throughput informatic and experimental approaches to functionally validate discoveries from genomic studies and advance them toward precision oncology. They share data and resources, such as analytical tools and reagents, across the Network and with the research community.

Map of the CTD² Centers

Each Center contributes unique expertise in one or more of the following areas:

  • In-depth mining of genomic data
  • Systems biology analyses
  • High-throughput screening of small molecules or genetic perturbagens
  • In vitro and in vivo biological characterization approaches
  • Cancer models (cell lines, organoids, PDXs)
  • Gene-gene dependencies (e.g., synthetic lethality)
  • Identification of interacting protein subunits in biochemical processes
  • Complex analytical approaches to target identification
  • Technology development and improvement

The following descriptions inform what each Center is contributing to the Network and the greater research community.

Current Phase

Preceding Phase